An ongoing dialogue on HIV/AIDS, infectious diseases,
March 10th, 2009
Unwelcome Visitor: Cost of HIV Meds
Those of us who practice HIV medicine in Taxachusetts (warning, click link at your peril) live a pretty charmed life, at least so far as getting HIV medications paid for. Due to an incredibly generous AIDS Drug Assistance Program (ADAP), rare is the patient who faces financial barriers getting his or her drugs.
(By the way, we abbreviate it “HDAP” here, not ADAP. And we treat early syphilis with two shots of penicillin, not one. And we voted for McGovern. And we drive on the left.)
But the recent downturn in the economy has changed this usually comfortable situation in the Bay State.
A patient of mine called to tell me that his co-pay for a 3 month supply of his antivirals is now nearly $2000. Another one has simply stopped coming to appointments, as his wife’s insurance has such a large deductible that he will only agree to blood tests, not an actual office visit. A third asked me whether he would be better off stopping enoxaparin or his HIV meds, since he couldn’t afford both.
I am sure things are much worse in other States — after all, Houston’s Joe Gathe initially tried lopinavir/r monotherapy since he reasoned that some ART was better than none, and his patients couldn’t afford triple-therapy.
Where is this headed? It’s tough to make predictions (especially about the future), but I suspect that when 3TC and saquinavir become generic, we might be turning to them more often than we’d previously thought.
Categories: Health Care, HIV, Infectious Diseases, Patient Care
Tags: 3tc, ADAP, aids drug assistance program, Cost, financial barriers, HDAP, HIV, hiv medications, HIV medicine, lopinavir, monotherapy, saquinavir, Taxachusetts
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
Sorry. No data so far.
-
From the Blog — Most Recent Articles
- Farewell to This Blog — and Hello to NEJM Voices March 2, 2026
- Some Ruminations on CROI — Still the Best HIV Meeting February 26, 2026
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing February 17, 2026
- Sometimes You Just Need to Get Input from a Real Human Being February 12, 2026
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
FROM NEJM — Recent Infectious Disease Articles- Minocycline-Induced Hyperpigmentation April 2, 2026A 68-year-old woman with rosacea presented with a 6-week history of dark patches on the skin of her arms and legs. Two weeks before the onset of the skin changes, she had started taking minocycline daily.
- Legislating Medicine — Directed Donation and the Politics of Patient Choice April 1, 2026A Tennessee bill focused on directed blood donation exemplifies a pattern of efforts to legislate medical practice in ways that override scientific consensus while invoking the language of autonomy.
- Probable Japanese Encephalitis Virus Transmission through Organ Transplantation March 26, 2026Infection with Japanese encephalitis virus, a mosquito-borne flavivirus, was identified in a patient who received a liver transplant from a donor who resided in California.
- Communicating about Vaccines in a Politically Contentious Climate March 26, 2026Recent changes in U.S. vaccine policy are sowing confusion and threatening the health of children and the wider population. How should pediatric clinicians communicate with parents to stem the damage?
- Eczema Herpeticum March 26, 2026A 33-year-old pregnant woman with previously controlled atopic dermatitis presented with 3 days of fever and an itchy, painful rash. Erythematous vesiculopapular lesions were noted on the face, neck, chest, and arms.
- Minocycline-Induced Hyperpigmentation April 2, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
